13F Pro Quality Score

Not in ranked universe

Pending next ranking run

This company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. Rankings refresh on Jan 1, Apr 1, Jul 1, Oct 1.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

Email me the moment this company reports earnings
AI Research Report
Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.
Upgrade to Pro
Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

BHVN Stock Analysis & AI Quality Score

Data updated 2026-07-26

AI stock analysis and institutional research for Biohaven Ltd. (BHVN), a Healthcare sector company. BHVN is not currently included in 13F Pro's AI-ranked quality universe — this company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. rankings refresh on jan 1, apr 1, jul 1, oct 1. Based on the latest XBRL financial filings (Q2 2026), Biohaven Ltd. reports net income of $-137.3M, free cash flow of $-85.6M. Top institutional holders of BHVN by reported 13-F value include BlackRock, SUVRETTA CAPITAL MANAGEMENT, STIFEL FINANCIAL, based on the most recent SEC filings. BHVN trades on the NYSE exchange and files with the SEC under CIK 1935979. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate BHVN daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Biohaven Ltd. directly from SEC EDGAR.

Net Income

Q2 2026

$-137.3M

Free Cash Flow

Q2 2026

$-85.6M

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Net Income

+12.7% YoY
$-738.8MFY 2025
FY22 $-570.3MFY23 $-408.2MFY24 $-846.4MFY25 $-738.8M

Operating Income

+15.8% YoY
$-745.4MFY 2025
FY22 $-567.9MFY23 $-436.1MFY24 $-885.1MFY25 $-745.4M

EPS (Diluted)

+26.1% YoY
$-6.86FY 2025
FY22 $-12.75FY23 $-5.73FY24 $-9.28FY25 $-6.86

Total Assets

-26.6% YoY
$451.4MFY 2025
FY22 $661.8MFY23 $513.2MFY24 $615.1MFY25 $451.4M

Op. Cash Flow

-4.6% YoY
$-609.4MFY 2025
FY22 $-297.7MFY23 $-331.7MFY24 $-582.5MFY25 $-609.4M

Free Cash Flow

-4.0% YoY
$-610.2MFY 2025
FY22 $-303.8MFY23 $-334.8MFY24 $-586.5MFY25 $-610.2M

Get alerted when BHVN's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Biohaven Ltd. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)
XBRL financial facts (revenue, EPS, margins)
Insider transactions (Form 4)
Institutional 13F holdings
Quality rankings (32 signals)
AI analyst debates & daily meetings
Historical financial trends
Peer comparison & sector analysis

Top Institutional Holders of BHVN

Put BHVN on your watchlist

Track score changes the day Biohaven Ltd. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Is BHVN a good stock to buy?

13F Pro's AI-powered analysis of Biohaven Ltd. (BHVN) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on NYSE). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for BHVN are available on the BHVN stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. BHVN is classified as a small company.

Which hedge funds own BHVN?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling BHVN. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Biohaven Ltd.'s investment landscape.